Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Yes, many of the companies you've invested in also have their own stock portfolios. This is bullishness worth noting.

These aren't for the faint of heart.

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

The stock looks cheap, but appearances can be deceiving.

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

The old healthcare model is breaking down.

Recursion (RXRX) Q1 2026 Earnings Transcript

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a pioneer in AI-driven clinical research, for a staggering $47.8 billion. The deal represents the largest "Tech-Bio" merger in

One of these is not like the other.

The convergence of two already fantastic industries is creating an incredible opportunity.

The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

It's not looking too good for the biotech.

Recursion (RXRX) Q4 2025 Earnings Call Transcript

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Ark Invest added to three positions that are well below last year's highs.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp (NASDAQ:NVDA) has fully exited its investment in the AI‑focused drug‑discovery company. Here's what you should know.

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a turbulent four-year period of consolidation and the "Great Rationalization," a surge of institutional capital and the industrialization of Artificial Intelligence (AI) have ignited